World-class Team of Tech, Pharma and Clinical Leaders Join Regulators and Patient  Advocates to Drive
the Development and Deployment of Digital Clinical Measures for Remote Patient Monitoring Through
COVID-19 Pandemic and Beyond

Boston, MA, NOVEMBER 18, 2020 – The Digital Medicine Society (DiMe) today announced its next open-science collaboration of stakeholders across clinical, technology, and nonprofit sectors, government, and academia to deploy The Digital Clinical Measures Playbook (The Playbook), the essential industry guide for remote patient monitoring in clinical research, clinical care and public health.

The goal of this ‘Tour of Duty’ is to drive adoption of The Playbook as the shared foundation for advancing digital clinical measurement and transforming clinical trials, patient care and public health through remote monitoring. 

“In recent years we’ve seen an explosion of promising digital health technologies from simple consumer health apps to sophisticated, evidence-based digital therapeutics to  treat disease,” said DiMe Executive Director Jennifer Goldsack. “The Playbook standardizes and guides the safe and effective use of digital clinical measures and helps to ensure an analytical and clinical evidence base for these technologies for the benefit of patients worldwide.”

The global COVID-19 pandemic has brought new urgency to the drive toward devising a common framework for the development and deployment of high quality, patient centric, digital clinical measures. Multiple digital technologies for symptom tracking and contact  tracing are currently in use and/or development, and clinical researchers are now designing new decentralized clinical trial strategies using telemedicine and remote patient monitoring to minimize pandemic-related disruption of the clinical research enterprise. Adoption of a comprehensive “how-to” roadmap to  synthesize best practices in the digital health field is essential for guiding these efforts and safeguarding public health. 

The Playbook, launched in September, 2020, was the culmination of a six-month Tour of Duty driven by multidisciplinary participants from DiMe, Elektra Labs; Genentech, a member of the Roche Group; Koneksa Health; MyoKardia; Sage Bionetworks; Scripps  Research; and the U.S. Food & Drug Administration.

Convened by DiMe for the second Tour, founding partners are joined by ActiGraph; Activinsights; American Pharmacists  Association; BlackThorne Therapeutics; Center for Digital Health at Brown University; Covance;  Digital.Health; Duke University; Eli Lilly and Company; the European Medicines Agency; Evidation Health; Merck and Co., Inc.; Open mHealth; Pfizer; physIQ; Savvy Coop; Takeda; VivoSense; and Winterlight Labs.

‘Tours of Duty’ (TOD) are the cornerstone of DiMe’s strategy for developing clinical  quality evidence on a rapid tech timeline. They are collaborative, open-science sprint efforts of four to six months, each addressing a pressing challenge needed to advance the safe, effective, ethical, and equitable use of digital technologies to improve public health. 

This next Tour is dedicated to establishing The Playbook as the shared foundation for digital clinical measurement and will drive several workstreams over the coming months to refine content and crystallize consensus, develop illustrative use cases, articulate optimal strategy and ROI for the use of remote monitoring, and advance educational initiatives. Conveners anticipate releasing these additional resources through April 2021.

What Tour of Duty participants are saying:

“We are on the brink of digital clinical measures going from being seen as “nice to have” to becoming critically important and absolutely necessary. The Playbook will help demonstrate to pharma companies, academic institutions and regulatory agencies the value of including digital endpoints in ALL clinical studies.” David Caouette, Executive Director, Head of Digital Data Science & the PfIRe Lab, ECD, Pfizer

“I see the great impact that can be made for patients when health can be measured outside of the clinic and with measures that matter to patients.” Bray Patrick-Lake,  Director of Strategic Partnerships, Evidation Health.

“This is a big opportunity to be part of something much bigger than any single project; being able to help shape the landscape and influence the digital health field is extremely exciting to me!” Jie Ren, Associate Principal Scientist, Merck & Co., Inc.

“(The Playbook) provides a common set of language, simple frameworks, grounded in practical user needs rather than theoretical issues. It’s simplified many conversations and we’re able to move faster when deploying digital tools into clinical trials.” Andy Coravos, CEO Elektra Labs.

“Digital clinical measures are new, exciting and very much under development. Having  a standard framework for their development and use will help the field move forward by setting best practices and encouraging adoption of these novel measures.” Jessica Robin, Director of Clinical Research, Winterlight Labs

“(The Playbook) helps provide objective clarity on including technology or new methods in projects.” Matt Biggs, Head of Business Operations, ActiGraph, LLC

The Playbook is available at

The Digital Medicine Society

The Digital Medicine Society (DiMe) is the professional society serving the digital medicine community. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health.

# # #

Media Contact
Staci L. Vernick
Communications, Digital Medicine Society

Savvylogo color full RBG



NEW YORK, NY AND BOSTON, MA, October 14, 2020The Digital Medicine Society (DiMe) is proud to announce the strategic partnership with Savvy Cooperative, the first and only patient-owned public benefit co-op. 

As DiMe builds the future of digital medicine, it is necessary to bring patient input into the development and deployment plans for digital medicine products. Simply, the field of digital medicine is made better when patients have the opportunity to fully participate as a valued stakeholder. Savvy is a leader in the field of patient engagement, from identifying barriers, opportunities, and success stories arising from engaging patients in the pharmaceutical industry, to highlighting racial inequalities that exist systematically across the healthcare ecosystem. 

Together, DiMe and Savvy are committed to working together as partners to champion meaningful patient engagement within the field of digital medicine by:

  • Serving as subject matter experts on the topics of digital medicine and patient engagement, respectively;
  • Connecting innovators and product development teams with diverse – yet targeted – patients and caregivers; 
  • Infusing best practices of patient engagement into the life cycle of connected health product development; and more. 

“It is DiMe’s privilege to partner with Savvy and bring the most important voices in healthcare – patients and their families – into meaningful conversations with innovators as we #askpatients. Together, we are building the future of medicine we want to see,” shares Rachel Chasse, DiMe’s Director of Innovation. The excitement for the future is echoed by Jennifer Horonjeff, founder and CEO of Savvy, adding, “we are thrilled to partner with DiMe – this is only the beginning!”

About Savvy Cooperative: Savvy Cooperative is the first and only patient-owned public benefit co-op, and accelerates the development of patient-centered products and solutions by providing a marketplace for patient insights. Companies can connect directly with diverse patients to participate in market research, user-testing, advisory boards and co-design opportunities. Using a unique co-op model, Savvy empowers patients to use their health experiences to advance research and product development. Savvy’s award-winning co-op has been featured in FastCompany, TechCrunch, The Boston Globe, and named one of the 50 Most Daring Entrepreneurs of 2018 by Entrepreneur Magazine.

About the Digital Medicine Society: At DiMe, our commitment to fully integrating experts from all of the disciplines comprising digital medicine is unwavering. From regulators to white-hat hackers, ethicists to engineers, and clinicians to citizen scientists, we are proud to welcome all experts committed to ensuring that digital medicine realizes its full potential to improve human health. Join us!


Jennifer Lannon - for Savvy
Business Development

Rachel Chasse - for DiMe 
Director of Innovation                     


US’ largest telehealth group launches new ‘Virtual-First’ healthcare initiative

Co-created by the Digital Medicine Society, ‘IMPACT’ aims to cultivate an ecosystem of organizations that view virtual care as their primary mission

Boston, MA, Jan 13, 2021 – In the midst of a global pandemic that has forced millions of healthcare professionals to become increasingly virtual, a new initiative for virtual healthcare is being launched today by the American Telemedicine Association and the Digital Medicine Society (DiMe).

The “IMPACT” initiative aims to go beyond conventional telemedicine efforts that are layered on top of existing healthcare organizations, and to instead develop solutions that its organizers call “virtual-first.”

IMPACT founding members include a wide range of digital-health start-ups, health-insurance companies, investors, and trade associations.

The initiative will also include research participation from Rock Health, a seed fund whose other partners include GE, Harvard Medical School and the Mayo Clinic.

DiMe executive director Jen Goldsack says that most services that we think of as telehealth have been developed to mirror traditional practice, using communications technologies to deliver an experience that aims to simulate an in-clinic visit.

“In contrast, virtual-first practices have staff and clinical workflows that are based exclusively on caring for patients remotely, and that don’t have to be reverse-engineered into existing workflows,” says Goldsack. “Virtual-first practices use technologies for patients to monitor their health at home, as well as offer care teams that might look a little different. They often include and coordinate needed diagnostics, therapeutics, remote patient monitoring, mental health professional consultations, coaching, nutrition consultation, together with physician services, all delivered outside of traditional healthcare facilities.”

Goldsack says that initial priorities include: 

    • developing model payer contracts for virtual-first organizations
    • conducting investor and innovator benchmarking surveys
    • addressing misconceptions that virtual care is “second-class medicine”

“Virtual-first practices experience many of the same challenges faced by all delivery systems and clinicians that practice telehealth, including difficulty securing reimbursement and outdated regulatory and licensing models,” added Ann Mond Johnson, CEO of the ATA. “They also have lacked a supportive ecosystem to help them thrive. That is, until now.”

IMPACT stands for “VIrtual-first Medical PrActice CollaboraTion.” Its steering committee includes representatives from the founding members as well as invited experts from across the field of digital medicine. 

Chair Donald Jones, a recognized leader in technology enabled health services and virtual clinic business models, says that the committee will discuss best practices and develop a shared vision and strategy for maximizing the impact of virtual-first care, and bringing healthcare payers into the fold.

“Virtual-first medical providers must offer complete turnkey healthcare solutions rather than the usual approach where patients are shuttled off from one siloed specialist to another only then to be sent to a diagnostic,” Jones says. “IMPACT will support this new subfield, convening representatives from across the ecosystem necessary to help virtual-first practices thrive.”

You can learn more about IMPACT at

The full list of founding members for the initiative include: 

    • Abridge
    • Aspen Rx Health
    • Axene Health Partners
    • Bind Benefits
    • Digital Therapeutics Alliance
    • Dreem
    • Elektra Labs
    • Freespira
    • Ginger
    • Guidewell Health
    • Independa
    • Omada Health
    • Oshi Health
    • Papa
    • Programma Health
    • Remedy
    • Takeda Digital Ventures
    • Tele911
    • TripleTree
    • Validic
    • Visana Health
    • KOLs, including patient experts

About IMPACT: Hosted by the Digital Medicine Society (DiMe) and the American Telemedicine Association (ATA), IMPACT is a pre-competitive collaboration of leading digital health companies, investors, payers, and consultants dedicated to supporting virtual-first medical organizations and their commitment to patient-centric care.

Media Contact 

Michelle Sechser 

(916) 320-7725

logo color full RBG

DiMe joins the Health Equity and Access Leadership (HEAL) Coalition toAddress How Health Technologies Can Close the Gap on Health Disparities

The Digital Medicine Society (DiMe) has joined the Consumer Technology Association (CTA) and the Connected Health Initiative (CHI)’s Health Equity and Access Leadership (HEAL) Coalition — a multi-sector initiative to create recommendations on the greater use of technology to mitigate health disparities, particularly coordination of resources, policy advocacy, research, and education.

The COVID-19 pandemic has further brought to light health disparities in America, adding credence that technology access is a social determinant of health. One example is the inequitable access to telehealth services experienced by female, non-English speaking, older, and lower-income patients, and that non-English language was independently associated with over 50% lower telemedicine usage compared to English-speaking patients. Further, Medicare data shows Black Americans were hospitalized with COVID-19 at a rate nearly four times higher than White Americans.

“Health technology holds the enormous possibility to help close the gap on health disparities, but only if these technologies are intentionally designed, built, and deployed to do so”, shares Rachel Chasse, DiMe’s Director of Innovation. “DiMe is thrilled to join the HEAL Coalition on this important initiative to help the next revolution in healthcare not miss the opportunity to deliberately serve the patients who have historically been left behind.”

The HEAL Coalition includes representatives from across the healthcare technology spectrum, including AT&T, Best Buy Health, Google, Microsoft, the University of Mississippi Medical Center, HP, Intel, Boston’s Children’s Hospital, and Rimidi, among others.

Victor Chan, Digital Health Platform Strategy Lead at Genentech, a member of the Roche Group, and Dr. Celine Marquez, Principal Scientist of Measurement Science at Genentech, and Chasse are the DiMe expert representatives serving on the HEAL Coalition working groups. In addition, DiMe will host a roundtable series for our member community, fostering discussion on the topics of health equity and access. True to DiMe’s values of community building and inclusivity, these roundtables allow for the collective power of collaboration where the many voices of our diverse members are heard and will influence our input to HEAL activities.

“Representing DiMe on the HEAL coalition is a natural extension of Genentech’s long-standing work to advance inclusive research and health equity,” said Chan and Marquez. “The coalition will help to ensure that health data translates into outstanding care, provides diverse patients access to innovative digital solutions, and improves outcomes for the most vulnerable.”

The HEAL Coalition’s first project will be a white paper with policy and operational recommendations addressing technology’s role in tackling disparities in the American healthcare system.

About the Digital Medicine Society: At DiMe, our commitment to fully integrating experts from all of the disciplines comprising digital medicine is unwavering. From regulators to white-hat hackers, ethicists to engineers, and clinicians to citizen scientists, we are proud to welcome all experts committed to ensuring that digital medicine realizes its full potential to improve human health. Join us​!


Rachel Chasse - for DiMe

Director of Innovation




health innovation hub and Digital Medicine Society launch partnership to advance

innovation in evidence generation to support broad acceptance of digital health applications

Berlin, 17. November, 2020 - An international group of researchers and experts in the use of real-world data and real-world evidence joined the health innovation hub (hih) and Digital Medicine Society (DiMe) this week in the first of a series of expert discussions and in launching the organizations’ partnership. 

The goal of the partnership between the hih and DiMe is to accelerate innovation in evidence generation related to digital health applications and speed the use of high quality digital medicine products in routine care by addressing the maldistribution of innovative policy vis-a-vis expertise in novel approaches to health research and evaluation. 

“Digital Medicine must be an evidence-based practice.” said DiMe Executive Director Jennifer Goldsack. “As digital innovation outpaces traditional clinical research timelines, we must find new approaches that deliver better information, faster." 

As part of Germany’s new Digital Healthcare Act (Digitale–Versorgung–Gesetz or DVG), the Fast-Track Process for Digital Health Applications (in German, Digitale Gesundheitsanwendungen, or DiGA, also known as “apps on prescription”) allows for digital technologies to be introduced into outpatient clinical practice and reimbursed by Germany’s statutory health insurers, with a concomitant goal of collecting real world performance data to accelerate high quality, digitally driven healthcare.

“Digital health applications (DiGA) finally have the opportunity to prove their effectiveness, supporting patients in managing and treating their diseases outside of the clinic, 24/7. These new digital solutions offer a plethora of novel capabilities and data sources, including direct insight into their use and usability in every-day life – the factors that matter most to patients. Yet we lack experience and research models to leverage the rich data that DiGA provide. I am grateful to DiMe and their vibrant community for sharing knowledge and supporting us in closing the gaps. In doing so, we become partners in building a better healthcare future” said Henrik Matthies, hih’s Managing Director. 

The innovative DVG legislation offers broad methodological flexibility to digital product manufacturers seeking to demonstrate the positive effects of their digital health applications. However, the scientists with the greatest experience in medical product development in Germany and Europe have, to date, focused almost exclusively on randomized controlled trials (RCTs) in the evidence generation process. Experience with novel study designs for high quality evidence generation is limited.

The research community in the United States has experience and expertise in using real-world data and novel study methodologies to generate high quality information. The international community has also developed approaches to challenges associated with the use of real-world data for regulatory and clinical decision-making such as lack of interoperability and non-representative data sets.

“The new DiGA-framework in Germany is another step towards a more digitalized healthcare system, but digital technologies also shed a light on a broader set of questions around the generation of evidence for healthcare outcomes: How do we address effectiveness in contrast to efficacy? Do we need a dynamic rather than a one-time assessment of (continuously refined) health technologies? And how do we develop and conduct such studies? By connecting the experience of the global health care research community with the innovative policy environment in Germany, we hope to stimulate innovative approaches to digital medical product evaluation” said Jan Brönneke, hih’s Director of Law and Economics Health Technologies

This month’s event identified a group of thought leaders and subject matter experts from within the German clinical research community as well as US-based experts with experience using real-world data and novel methodologies to generate high quality evidence of medical product performance. 

Over the coming months, the hih and DiMe will convene an additional expert event and will build out a selection of illustrative examples of novel approaches to health evaluation research that can be readily applied to the evaluation of DiGA in Germany and novel digital health applications more broadly. Further, the organizations will partner in hosting the English-language program of Digital Medicine Week on the 3. and 4. of February, 2021. 

“We are energized by the unique opportunity to build a trans-Atlantic collaborative community of researchers committed to the high quality evaluation of digital medicine products using real-world data sets and novel methodologies” said Julia Hagen, hih’s Director of Regulatory and Politics. 

Digital Medicine Week will feature a half-day long “Evidence Con” (evidence generation convention) and “Research-a-thon” (study design sprint) that will give aspiring medical entrepreneurs and researchers a chance to learn from international experts and gain hands-on experience in the design of novel, high quality evidence-generation studies for DiGA. For more information and to register for Digital Medicine Week, see

About the health innovation hub

The health innovation hub (hih) serves as a think tank, sparring partner, and implementation supporter for the Federal Ministry of Health and its subordinate authorities, among others. The team was set up as a point of contact and bridge between all major stakeholders of the German health care system. For more information about the hih and our work, please visit

About the Digital Medicine Society 

Founded in 2019, the Digital Medicine Society (DiMe) is the first professional organization for experts from all disciplines comprising the diverse field of digital medicine. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health. DiMe is a 501(c)(3) non-profit organization dedicated to advancing digital medicine to optimize human health. We do this by serving professionals at the intersection of the global healthcare and technology communities, supporting them in developing digital medicine through interdisciplinary collaboration, research, teaching, and the promotion of best practices. For more information about DiMe and to view our work please visit 

# # #


Claudia Dirks for hih

Michelle Sechser for DiMe

logo color full RBG

DiMe Joins FDA’s Network of Experts


Boston, MA -- November 10, 2020 -- The Digital Medicine Society (DiMe), the professional society for the digital medicine community, has joined the U.S. Food & Drug Administration’s (FDA) “Network of Experts”. 

FDA’s Network of Experts is a vetted network of partner organizations and their member scientists, clinicians and engineers who can provide the FDA rapid access to expertise when it is needed to supplement existing knowledge and expertise within the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER).

This announcement follows the recent launch of FDA’s new Digital Health Center of Excellence (DHCoE), which aims to boost digital health innovation by fostering partnerships and connections among digital health stakeholders.

“Participation in FDA’s Network of Experts provides DiMe members with a unique opportunity to further our collective efforts to advance the safe, effective, ethical, and equitable use of digital technologies to optimize health,” said DiMe Executive Director, Jennifer Goldsack. “This underscores both the breadth and depth of the expertise that defines the DiMe membership and we are proud to support FDA initiatives across the agency that seek to use digital technologies to advance healthcare for everyone.”


About the Digital Medicine Society 

The Digital Medicine Society (DiMe) is the professional organization for experts from all disciplines comprising the diverse field of digital medicine. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health. From regulators to white-hat hackers, ethicists to engineers, and clinicians to citizen scientists, we are a community at the intersection of the global healthcare and technology communities dedicated to advancing digital medicine to optimize human health. @_DiMeSociety

#    #    #


Michelle Sechser - for DiMe
(916) 320-7725



covid 19 healthcare coalition

COVID-19 Healthcare Coalition Surveys Physicians on Telehealth Impact During COVID-19 

Nationwide Survey Finds Overall Satisfaction but Obstacles Remain 

McLean, VA, and Bedford, MA, November 17, 2020 — Today the COVID-19 Healthcare Coalition – comprising more than 1,000 healthcare organizations, technology firms, and nonprofits – published the Telehealth Impact Physician Survey. More than 75% of respondents said telehealth enabled them to provide quality care for COVID-19-related care, acute care, chronic disease management, hospital/emergency department follow-up, care coordination, preventative care, and mental/behavioral health. 

The 48-question survey captured the opinions of 1,594 physicians and other qualified healthcare professionals between July 13 and August 15, 2020. Among those surveyed, 87% were medical doctors and 13% were non-physician providers including nurse practitioners, psychologists, physician assistants, and social workers. 

The survey is part of the Telehealth Impact Study prepared by the coalition’s Telehealth Work Group, comprised of the American Medical Association, American Telemedicine Association, Change Healthcare, Digital Medicine Society, Massachusetts Health Quality Partners, MassChallenge HealthTech, Mayo Clinic, and MITRE. 

Topline findings show strong support for telehealth: 

    • 60% reported that telehealth has improved the health of their patients. 
    • 68% report they’re motivated to increase telehealth use in their practices. 
    • 11% said they were using remote patient monitoring technologies with patients in their homes. Commonly used tools included smartphones, blood pressure cuffs, body weight scales, and pulse oximeters. 
    • 55% indicated that telehealth has improved the satisfaction of their work. 
    • More than 80% of respondents indicated that telehealth improved the timeliness of care for their patients. A similar percentage said that their patients have reacted favorably to using telehealth for care. 

“The strong support shown for telehealth, as evidenced in these results, reinforces the knowledge that telehealth is critical to how we deliver healthcare today,” said Dr. Steve Ommen, medical director, Mayo Clinic Center for Connected Care, and one of the study’s co-investigators. “The use of telehealth during the COVID-19 pandemic highlights its importance in care delivery. Its continued use will be instrumental in connecting to patients everywhere.” 

Barriers and Challenges 

The survey also found barriers and challenges still exist and/or are anticipated beyond the pandemic. For example: 

    •  73.3% indicated that no or low reimbursement will be a major challenge post-COVID. (Note: The government adapted many regulations to enable telehealth during the pandemic.)
    • More than 64% said technology challenges for patients were a barrier to the sustainable use of telehealth. These perceived challenges included lack of access to technology and/or internet/broadband, as well as low digital literacy.
    • 58% are not able to currently access their telehealth technology directly from their electronic health records.  

Dr. John Halamka, president of the Mayo Clinic Platform and co-chair of the coalition, said, "In addition to technology and policy change during covid-19, we've had culture change. Patients will expect more virtual care even after we return to the new normal post vaccination." 

Dr. Jay Schnitzer, MITRE’s chief medical and technology officer and co-chair of the coalition, added, “COVID-19 has severely tested our nation’s healthcare delivery. As we navigate this pandemic, we need to evaluate the efficacy of all tools available to serve patients safely. This survey provides valuable insight into physicians’ adoption of telehealth, and we look forward to adding the patients’ perspective in the near future.” 

Views from Members of the COVID-19 Healthcare Coalition Telehealth Work Group 

    • Dr. Susan R. Bailey, president, American Medical Association (AMA)  

“Telehealth and remote care services have proven critical to the management of COVID-19, while also ensuring uninterrupted care for 100 million Americans with chronic conditions. How telehealth will be used after the pandemic is in the balance, and no one wants to see new access to telehealth suddenly halted. The time is now for government officials, physicians, patients, and other stakeholders to work together on a solid plan to support telehealth services going forward. Future telehealth policies should be data driven, and the Telehealth Impact Study provides important insights to guide necessary decisions.” 

    • Ann Mond Johnson, chief executive officer, American Telemedicine Association (ATA)  

“As evidenced by the results of the Telehealth Impact Physician Survey, COVID-19 has allowed telehealth to prove its value as a safe, effective, and necessary care delivery option that can provide quality care to patients when and where they need it. Telehealth is also helping to address several challenges that have been exacerbated by and will continue long after the pandemic, including a severe provider shortage and a growing gap in access to care for rural communities and our most vulnerable populations. Telehealth did not create these problems but offers a cost-effective solution to a failing healthcare system. By extending access to care, improving efficiencies, and reducing healthcare spending, telehealth creates a hybrid care delivery system of in-person and virtual care, bringing healthcare into the 21st century.” 

    • Tim Suther, senior vice president and general manager, data solutions, Change Healthcare  

“Helping the COVID-19 Healthcare Coalition produce important findings is crucial to everyone’s overall health and well-being during the pandemic. These findings provide critical insights to healthcare policy and strategy decision makers, and will help to enable superior healthcare experiences for both patients and their care providers.” 

    • Jennifer Goldsack, executive director, Digital Medicine Society (DiMe)  

“The COVID-19 pandemic has driven the rapid adoption of telehealth. The Telehealth Impact Study provides some of the first evidence that the increase in remote patient monitoring has been much more limited. This critical finding demands further exploration to ensure that the full promise of high-quality telehealth is realized and sustainable over time.” 

    • Barbra G. Rabson, president and chief executive officer, Massachusetts Health Quality Partners (MHQP)  

“In MHQP’s work surveying clinicians about their telehealth experiences we have found a high degree of variation with clinician satisfaction and adaption of telehealth. Clearly telehealth can fill an important and longstanding need in our health system, but we still have a long way to go to make telehealth a viable option for all patients." 

    • Nick Dougherty, managing director, MassChallenge HealthTech (MCHT 

"It’s clear that telehealth is here to stay. As we’ve seen firsthand throughout the pandemic, digital solutions in healthcare can have a transformative impact on patients’ lives. But these solutions must have the right incentive structures to truly realize their full potential. In the Telehealth Impact Study, we found digital access to care is not only possible across a variety of indications, but also to a high degree of satisfaction." 

    • Dr. Francis X. Campion, co-investigator, MITRE  

“During COVID-19 the move to telehealth has been broad and deep, serving patients with a wide variety of health needs in every state. We are learning rapidly and now have the responsibility to integrate digital methods into the workflow to improve the value of care.” 


About the COVID-19 Healthcare Coalition 

The COVID-19 Healthcare Coalition is a private-sector-led response to the COVID-19 pandemic that brings together healthcare organizations, technology firms, nonprofits, academia, and startups. It coordinates members’ collective expertise, capabilities, data, and insights to preserve the healthcare delivery system and help protect U.S. populations. Learn more at


The coalition is seeking individuals 18 or older, living in the U.S., who have had a telehealth visit during the COVID-19 period since March 11, 2020, to take a survey of their impressions of telehealth. More information is available at


Mike Murphy -- for Mitre 

Michelle Sechser - for DiMe

ata dime




WASHINGTON, DC, AND BOSTON, March 25, 2020 -- ATA, the premier organization working to accelerate the adoption of telehealth, and the Digital Medicine Society (DiMe), the professional society serving the digital medicine community, today announced a new strategic partnership to demonstrate the value of connected technologies in solving some of today's most pressing challenges to health, healthcare and health research. 

"The coronavirus pandemic has brought to light the critical role telehealth can play in care delivery -- improving access to care and enabling the timely and effective treatment of patients outside of a healthcare setting," said Ann Mond Johnson, CEO, the ATA. "Telehealth will fast become the workhorse of our healthcare system as we come out of this health crisis, creating a more patient-centered, personalized and convenient level of care. We are pleased to partner with DiMe to advance awareness, galvanize stakeholders and promote the widespread acceptance for this important care modality."

The ATA and DiMe represent two leading organizations that share a common philosophy and engage in complementary efforts. Their collaboration will focus on thought leadership activities, including efforts to measure and improve how antibiotics are prescribed via a virtual visit and used by patients; policy initiatives and research projects to establish priorities and promote best practices. 

"Telehealth and digital medicine are not the promise of the future, they are already here. However, there still exists a gap in our ability to demonstrate that digital tools are worthy of the trust we are asking society to place in them," added Jennifer Goldsack, Executive Director, DiMe. "By combining our applied research focus with the ATA's significant industry voice and the practical and diverse expertise of our collective membership, we can unlock the full potential of telehealth and digital medicine to improve the lives of the patients we exist to serve."

About the ATA

As the only organization completely focused on advancing telehealth, the ATA is committed to ensuring that everyone has access to safe, affordable, and appropriate care when and where they need it, enabling the system to do more good for more people. ATA represents a broad and inclusive member network of technology solution providers and payers, as well as partner organizations and alliances, working to advance industry adoption of telehealth, promote responsible policy, advocate for government and market normalization, and provide education and resources to help integrate virtual care into emerging value-based delivery models. @americantelemed #gotelehealth

About the Digital Medicine Society
The Digital Medicine Society (DiMe) is the professional organization for experts from all disciplines comprising the diverse field of digital medicine. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health. From regulators to white-hat hackers, ethicists to engineers, and clinicians to citizen scientists, we are a community at the intersection of the global healthcare and technology communities dedicated to advancing digital medicine to optimize human health. @_DiMeSociety

# # #





Gina Cella - for the ATA
Cella Communications
(857) 239-9198

Michelle Sechser - for DiMe
(916) 320-7725